1
|
Al-Hawary SIS, Abdalkareem Jasim S, Altalbawy FMA, Kumar A, Kaur H, Pramanik A, Jawad MA, Alsaad SB, Mohmmed KH, Zwamel AH. miRNAs in radiotherapy resistance of cancer; a comprehensive review. Cell Biochem Biophys 2024:10.1007/s12013-024-01329-2. [PMID: 38805114 DOI: 10.1007/s12013-024-01329-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/18/2024] [Indexed: 05/29/2024]
Abstract
While intensity-modulated radiation therapy-based comprehensive therapy increases outcomes, cancer patients still have a low five-year survival rate and a high recurrence rate. The primary factor contributing to cancer patients' poor prognoses is radiation resistance. A class of endogenous non-coding RNAs, known as microRNAs (miRNAs), controls various biological processes in eukaryotes. These miRNAs influence tumor cell growth, death, migration, invasion, and metastasis, which controls how human carcinoma develops and spreads. The correlation between the unbalanced expression of miRNAs and the prognosis and sensitivity to radiation therapy is well-established. MiRNAs have a significant impact on the regulation of DNA repair, the epithelial-to-mesenchymal transition (EMT), and stemness in the tumor radiation response. But because radio resistance is a complicated phenomena, further research is required to fully comprehend these mechanisms. Radiation response rates vary depending on the modality used, which includes the method of delivery, radiation dosage, tumor stage and grade, confounding medical co-morbidities, and intrinsic tumor microenvironment. Here, we summarize the possible mechanisms through which miRNAs contribute to human tumors' resistance to radiation.
Collapse
Affiliation(s)
| | | | - Farag M A Altalbawy
- Department of Chemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia
| | - Ashwani Kumar
- Department of Life Sciences, School of Sciences, Jain (Deemed-to-be) University, Bengaluru, Karnataka, 560069, India
- Department of Pharmacy, Vivekananda Global University, Jaipur, Rajasthan, 303012, India
| | - Harpreet Kaur
- School of Basic & Applied Sciences, Shobhit University, Gangoh, Uttar Pradesh, 247341, India
- Department of Health & Allied Sciences, Arka Jain University, Jamshedpur, Jharkhand, 831001, India
| | - Atreyi Pramanik
- School of Applied and Life Sciences, Divison of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India
| | | | - Salim Basim Alsaad
- Department of Pharmaceutics, Al-Hadi University College, Baghdad, 10011, Iraq
| | | | - Ahmed Hussein Zwamel
- Medical Laboratory Technique College, The Islamic University, Najaf, Iraq
- Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq
- Medical Laboratory Technique College, The Islamic University of Babylon, Babylon, Iraq
| |
Collapse
|
2
|
Yang R, Wang P, Lou K, Dang Y, Tian H, Li Y, Gao Y, Huang W, Zhang Y, Liu X, Zhang G. Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2022; 9:e2104728. [PMID: 35170876 PMCID: PMC9036023 DOI: 10.1002/advs.202104728] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 01/07/2022] [Indexed: 05/19/2023]
Abstract
Positive resection margin frequently exists in breast-conserving treatment (BCT) of early-stage breast cancer, and insufficient therapeutic efficacy is common during radiotherapy (RT) in advanced breast cancer patients. Moreover, a multimodal nanotherapy platform is urgently required for precision cancer medicine. Therefore, a biodegradable cyclic RGD pentapeptide/hollow virus-like gadolinium (Gd)-based indocyanine green (R&HV-Gd@ICG) nanoprobe is developed to improve fluorescence image-guided surgery and breast cancer RT efficacy. R&HV-Gd exhibits remarkably improved aqueous stability, tumor retention, and target specificity of ICG, and achieves outstanding magnetic resonance/second near-infrared (NIR-II) window multimodal imaging in vivo. The nanoprobe-based NIR-II fluorescence image guidance facilitates complete tumor resection, improves the overall mouse survival rate, and effectively discriminates between benign and malignant breast tissues in spontaneous breast cancer transgenic mice (area under the curve = 0.978; 95% confidence interval: 0.952, 1.0). Moreover, introducing the nanoprobe to tumors generated more reactive oxygen species under X-ray irradiation, improved RT sensitivity, and reduced mouse tumor progression. Notably, the nanoprobe is biodegradable in vivo and exhibits accelerated bodily clearance, which is expected to reduce the potential long-term inorganic nanoparticle toxicity. Overall, the nanoprobe provides a basis for developing precision breast cancer treatment strategies.
Collapse
Affiliation(s)
- Rui‐Qin Yang
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Pei‐Yuan Wang
- Key Laboratory of Design and Assembly of Functional NanostructuresFujian Institute of Research on the Structure of MatterChinese Academy of SciencesFuzhouFujian350000China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujian350025China
| | - Kang‐Liang Lou
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Yong‐Ying Dang
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Hai‐Na Tian
- Department of BiomaterialsCollege of MaterialsResearch Center of Biomedical Engineering of Xiamen and Key Laboratory of Biomedical Engineering of Fujian Province and Fujian Provincial Key Laboratory for Soft Functional Materials ResearchXiamen UniversityXiamenFujian361005China
| | - Yang Li
- Key Laboratory of Design and Assembly of Functional NanostructuresFujian Institute of Research on the Structure of MatterChinese Academy of SciencesFuzhouFujian350000China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujian350025China
| | - Yi‐Yang Gao
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Wen‐He Huang
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Yong‐Qu Zhang
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| | - Xiao‐Long Liu
- Key Laboratory of Design and Assembly of Functional NanostructuresFujian Institute of Research on the Structure of MatterChinese Academy of SciencesFuzhouFujian350000China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujian350025China
| | - Guo‐Jun Zhang
- Cancer Center and Department of Breast and Thyroid SurgeryXiang'an Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamenFujian361100China
- Key Laboratory for Endocrine‐Related Cancer Precision Medicine of XiamenXiang'an Hospital of Xiamen UniversityXiamenFujian361100China
- Cancer Research CenterSchool of MedicineXiamen UniversityXiamenFujian361100China
- Xiamen Research Center of Clinical Medicine in Breast & Thyroid CancersXiamenFujian361100China
| |
Collapse
|
3
|
Shi Y, Wang Y, Jiang H, Sun X, Xu H, Wei X, Wei Y, Xiao G, Song Z, Zhou F. Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca 2+] m-PDP1-PDH-histone acetylation retrograde signaling. Cell Death Dis 2021; 12:837. [PMID: 34489398 PMCID: PMC8421510 DOI: 10.1038/s41419-021-03984-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2020] [Revised: 04/23/2021] [Accepted: 04/26/2021] [Indexed: 12/19/2022]
Abstract
Mitochondrial retrograde signaling (mito-RTG) triggered by mitochondrial dysfunction plays a potential role in regulating tumor metabolic reprogramming and cellular sensitivity to radiation. Our previous studies showed phos-pyruvate dehydrogenase (p-PDH) and PDK1, which involved in aerobic glycolysis, were positively correlated with radioresistance, but how they initiate and work in the mito-RTG pathway is still unknown. Our further genomics analysis revealed that complex I components were widely downregulated in mitochondrial dysfunction model. In the present study, high expression of p-PDH was found in the complex I deficient cells and induced radioresistance. Mechanistically, complex I defects led to a decreased PDH both in cytoplasm and nucleus through [Ca2+]m-PDP1-PDH axis, and decreased PDH in nucleus promote DNA damage repair (DDR) response via reducing histone acetylation. Meanwhile, NDUFS1 (an important component of the complex I) overexpression could enhance the complex I activity, reverse glycolysis and resensitize cancer cells to radiation in vivo and in vitro. Furthermore, low NDUFS1 and PDH expression were validated to be correlated with poor tumor regression grading (TRG) in local advanced colorectal cancer (CRC) patients underwent neoadjuvant radiotherapy. Here, we propose that the [Ca2+]m-PDP1-PDH-histone acetylation retrograde signaling activated by mitochondrial complex I defects contribute to cancer cell radioresistance, which provides new insight in the understanding of the mito-RTG. For the first time, we reveal that NDUFS1 could be served as a promising predictor of radiosensitivity and modification of complex I function may improve clinical benefits of radiotherapy in CRC.
Collapse
Affiliation(s)
- Yingying Shi
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - You Wang
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Huangang Jiang
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Xuehua Sun
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Hui Xu
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Xue Wei
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Yan Wei
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Guohui Xiao
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Zhiyin Song
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, Hubei, 430071, China
| | - Fuxiang Zhou
- Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
- Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
- Hubei clinical cancer study center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
| |
Collapse
|
4
|
Xu M, Gong S, Li Y, Zhou J, Du J, Yang C, Yang M, Zhang F, Liang C, Tong Z. Identifying Long Non-coding RNA of Prostate Cancer Associated With Radioresponse by Comprehensive Bioinformatics Analysis. Front Oncol 2020; 10:498. [PMID: 32318351 PMCID: PMC7154134 DOI: 10.3389/fonc.2020.00498] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Accepted: 03/19/2020] [Indexed: 12/01/2022] Open
Abstract
Although radiotherapy is greatly successful in the treatment of prostate cancer (PCa), radioresistance is still a major challenge in the treatment. To our knowledge, this study is the first to screen long non-coding RNAs (lncRNAs) associated with radioresponse in PCa by The Cancer Genome Atlas (TCGA). Bioinformatics methods were used to identify the differentially expressed lncRNAs and protein-coding genes (PCGs) between complete response (CR) and non-complete response (non-CR) groups in radiotherapy. Statistical methods were applied to identify the correlation between lncRNAs and radioresponse as well as lncRNAs and PCGs. The correlation between PCGs and radioresponse was analyzed using weighted gene co-expression network analysis (WGCNA). The three online databases were used to predict the potential target miRNAs of lncRNAs and the miRNAs that might regulate PCGs. RT-qPCR was utilized to detect the expression of lncRNAs and PCGs in our PCa patients. A total of 65 differentially expressed lncRNAs and 468 differentially expressed PCGs were found between the two groups of PCa. After the chi-square test, LINC01600 was selected to be highly correlated with radioresponse from the 65 differentially expressed lncRNAs. Pearson correlation analysis found 558 PCGs co-expressed with LINC01600. WGCNA identified the darkred module associated with radioresponse in PCa. After taking the intersection of the darkred module of WGCNA, differentially expressed PCGs between the two groups of PCa, and the PCGs co-expressed with LINC01600, three PCGs, that is, JUND, ZFP36, and ATF3 were identified as the potential target PCGs of LINC01600. More importantly, we detected the expression of LINC01600 and three PCGs using our PCa patients, and finally verified that LINC01600 and JUND were differentially expressed between CR and non-CR groups, excluding ZFP36 and ATF3. Meantime, the potential regulation ability of LINC01600 for JUND in PCa cell lines was initially explored. In addition, we constructed the competing endogenous RNA (ceRNA) network of LINC01600—miRNA—JUND. In conclusion, we initially reveal the association of LINC01600 with radioresponse in PCa and identify its potential target PCGs for further basic and clinical research.
Collapse
Affiliation(s)
- Meng Xu
- Department of Radiation Oncology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
| | - Shiqi Gong
- Department of Otolaryngology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Yue Li
- Department of Radiation Oncology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
| | - Jun Zhou
- Department of Urology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.,Institute of Urology, Anhui Medical University, Heifei, China
| | - Junhua Du
- Department of Urology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.,Institute of Urology, Anhui Medical University, Heifei, China
| | - Cheng Yang
- Department of Urology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.,Institute of Urology, Anhui Medical University, Heifei, China
| | - Mingwei Yang
- Department of Radiation Oncology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
| | - Fan Zhang
- Department of Radiation Oncology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
| | - Chaozhao Liang
- Department of Urology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.,Institute of Urology, Anhui Medical University, Heifei, China
| | - Zhuting Tong
- Department of Radiation Oncology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
| |
Collapse
|
5
|
Karbaschi M, Ji Y, Abdulwahed AMS, Alohaly A, Bedoya JF, Burke SL, Boulos TM, Tempest HG, Cooke MS. Evaluation of the Major Steps in the Conventional Protocol for the Alkaline Comet Assay. Int J Mol Sci 2019; 20:E6072. [PMID: 31810189 PMCID: PMC6929057 DOI: 10.3390/ijms20236072] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/26/2019] [Accepted: 11/28/2019] [Indexed: 11/16/2022] Open
Abstract
Single cell gel electrophoresis, also known as the comet assay, has become a widespread DNA damage assessment tool due to its sensitivity, adaptability, low cost, ease of use, and reliability. Despite these benefits, this assay has shortcomings, such as long assay running time, the manipulation of multiple slides, individually, through numerous process steps, the challenge of working in a darkened environment, and reportedly considerable inter- and intra-laboratory variation. All researchers typically perform the comet assay based upon a common core approach; however, it appears that some steps in this core have little proven basis, and may exist, partly, out of convenience, or dogma. The aim of this study was to critically re-evaluate key steps in the comet assay, using our laboratory's protocol as a model, firstly to understand the scientific basis for why certain steps in the protocol are performed in a particular manner, and secondly to simplify the assay, and decrease the cost and run time. Here, the shelf life of the lysis and neutralization buffers, the effect of temperature and incubation period during the lysis step, the necessity for drying the slides between the electrophoresis and staining step, and the need to perform the sample workup and electrophoresis steps under subdued light were all evaluated.
Collapse
Affiliation(s)
- Mahsa Karbaschi
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
- Department of Human and Molecular Genetics, Florida International University, Miami, FL 33199, USA
| | - Yunhee Ji
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
| | - Abdulhadi Mohammed S. Abdulwahed
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
| | - Alhanoof Alohaly
- Department of Dietetics and Nutrition, Florida International University, Miami, FL 33199, USA;
| | - Juan F. Bedoya
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
| | - Shanna L. Burke
- School of Social Work, Florida International University, Miami, FL 33199, USA;
| | - Thomas M. Boulos
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
| | - Helen G. Tempest
- Department of Human and Molecular Genetics, Florida International University, Miami, FL 33199, USA
- Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA
| | - Marcus S. Cooke
- Oxidative Stress Group, Department of Environmental Health Sciences, Florida International University, Miami, FL 33199, USA; (Y.J.); (A.M.S.A.); (J.F.B.); (T.M.B.); (M.S.C.)
- Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA
| |
Collapse
|